Immune Design clinical trials
Acquired by Merck & Co., Inc, Apr 2, 2019 · source ↗
The registry lists 7 studies whose lead sponsor is Immune Design. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2020.
Before and after it joined Merck & Co., Inc
- First submitted before Immune Design became part of Merck & Co., Inc
- 7
- First submitted after Immune Design became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)7 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Merck & Co., Inc studies →
- Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)TerminatedNCT02501473Phase 1/2
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)TerminatedNCT02609984Phase 2
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1TerminatedNCT02387125Phase 1
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)TerminatedNCT03520959Phase 3
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1CompletedNCT02122861Phase 1
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell CarcinomaCompletedNCT02035657Phase 1
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc
- A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic CancerCompletedNCT02015416Phase 1
Sponsor listed in the registry: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Immune Design became part of Merck & Co., Inc